Last updated: November 3, 2026
Cortisone acetate is a mature, low-cost corticosteroid with no meaningful remaining composition-of-matter exclusivity. Its market is driven by generic supply, hospital and pharmacy procurement, clinical substitution with hydrocortisone and prednisone, and occasional supply disruptions rather than branded innovation. Public companies do not separately disclose material revenue for cortisone acetate, so the product’s financial trajectory is best assessed through prescription demand, generic pricing, manufacturing concentration, and reimbursement economics.
What is the current market position of cortisone acetate?
Cortisone acetate is an orally administered glucocorticoid used for corticosteroid replacement and inflammatory or immune-mediated conditions. It is converted in the body to hydrocortisone and is less potent on a milligram basis than dexamethasone or prednisone.
In the United States, marketed products are primarily generic tablets in 5 mg, 10 mg, and 25 mg strengths. The product is generally sold through retail pharmacies, wholesalers, hospitals, and institutional purchasing channels. The market has the following characteristics:
| Market factor |
Assessment |
| Product type |
Small-molecule oral corticosteroid |
| Primary dosage form |
Immediate-release tablets |
| Brand status |
Historical brand products, including Cortone, are generally discontinued or commercially marginal |
| Current supply |
Generic manufacturers and contract suppliers |
| FDA pathway |
Abbreviated New Drug Application, or ANDA, pathway for most current products |
| Prescription economics |
Low unit price, low total revenue per patient |
| Demand profile |
Chronic replacement therapy and intermittent inflammatory treatment |
| Substitution risk |
High; hydrocortisone, prednisone, and other corticosteroids compete directly |
| Patent barrier |
No commercially relevant active original-molecule patent barrier |
| Biosimilar exposure |
None; cortisone acetate is a conventional small molecule |
Cortisone acetate remains clinically relevant because some patients require oral glucocorticoid replacement and because clinicians may use it when a specific corticosteroid profile is preferred. Its commercial position is weaker than hydrocortisone, which is more commonly used for physiologic replacement and is available across broader dosage-form categories.
How large is the cortisone acetate market?
No major manufacturer publicly reports global or U.S. revenue for cortisone acetate as a standalone product. Public company filings generally aggregate mature generic products into broader categories. Prescription databases may report utilization, but commercial revenue estimates differ by source, dosage strength, payer channel, and whether hospital purchases are included.
The financial market is therefore best characterized as a small, fragmented generic segment rather than a separately reported pharmaceutical franchise.
Revenue is constrained by four factors:
- Low generic pricing.
- Limited patient spending per prescription.
- Extensive therapeutic substitution.
- Absence of differentiated delivery technology or branded promotion.
Revenue can still rise temporarily when a manufacturer faces a shortage, a supplier exits, or a wholesaler reallocates inventory. Those events can increase average selling prices without creating durable franchise value. The increase generally benefits suppliers with available inventory rather than the entire market.
What drives demand for cortisone acetate?
Demand comes from several sources:
- Long-term adrenal replacement therapy.
- Treatment of inflammatory and autoimmune disorders.
- Patients stabilized on an existing regimen.
- Prescribers seeking an oral cortisone product when hydrocortisone or prednisone is unsuitable.
- Institutional formularies that maintain multiple corticosteroid options.
Demand is relatively inelastic for patients who rely on the drug for replacement therapy. It is more elastic in inflammatory indications because physicians can substitute prednisone, hydrocortisone, methylprednisolone, or dexamethasone.
The product has a lower growth ceiling than newer corticosteroids because it has no novel mechanism, no extended-release technology, and no exclusivity-supported indication expansion.
What patents protect cortisone acetate?
The original composition-of-matter and product patents for cortisone acetate expired decades ago. Cortisone acetate was introduced in the mid-20th century, and the historical patent estate cannot create a present-day barrier to generic entry.
Current commercial protection does not depend on a live molecule patent. Potentially relevant intellectual-property categories would include:
- Tablet formulation patents.
- Manufacturing-process patents.
- Solid-state or crystal-form patents.
- Packaging or stability patents.
- Method-of-use patents.
For a simple immediate-release cortisone acetate tablet, these categories have limited practical value. A generic applicant can usually design around narrow formulation or process claims, and an old active ingredient provides little basis for a commercially meaningful secondary patent program.
What is the Orange Book status of cortisone acetate?
FDA Orange Book protection for a conventional generic product is generally limited where no unexpired listed patents or regulatory exclusivities remain. Public FDA resources should be reviewed by strength, manufacturer, and application number because listings can change when products are withdrawn or new ANDAs are approved.
The commercial conclusion is clear: cortisone acetate does not have a meaningful Orange Book patent barrier comparable to newer branded drugs. Any ANDA applicant typically faces the ordinary generic approval process rather than a molecule-level patent challenge.
FDA Orange Book listings can include patent information for approved applications, but the absence of a significant listed patent estate does not eliminate other regulatory or manufacturing requirements. An applicant must still demonstrate pharmaceutical equivalence, bioequivalence where applicable, chemistry and manufacturing controls, and compliance with current good manufacturing practice requirements (FDA, 2024a).
When did cortisone acetate lose exclusivity?
Cortisone acetate lost effective exclusivity many decades ago. The product predates the modern Hatch-Waxman framework, and any original approval exclusivity is no longer commercially relevant.
| Exclusivity category |
Current commercial relevance |
| Original composition patent |
Expired |
| Original product patent |
Expired |
| New chemical entity exclusivity |
Not applicable to current products |
| Orphan-drug exclusivity |
Not a general market barrier |
| Pediatric exclusivity |
Not a current barrier |
| Formulation exclusivity |
No widely recognized market-defining barrier |
| Regulatory data exclusivity |
Expired or irrelevant for current generic supply |
The absence of exclusivity means that market entry depends primarily on FDA approval, manufacturing capability, product economics, and supply-chain access.
Which companies manufacture or compete with cortisone acetate?
The U.S. supply base has historically included generic manufacturers and marketing companies such as Hikma Pharmaceuticals, Amneal Pharmaceuticals, Solco Healthcare, and other ANDA holders or distributors, depending on the dosage strength and current product status. Manufacturer participation can change as companies discontinue products, transfer applications, or rely on contract manufacturing.
A complete current manufacturer list requires a live review of FDA Drugs@FDA, the Orange Book, and National Drug Code records. Product availability is often more important than the number of approved applications because not every approved ANDA is actively marketed.
How does cortisone acetate compare with hydrocortisone and prednisone?
| Attribute |
Cortisone acetate |
Hydrocortisone |
Prednisone |
| Drug class |
Glucocorticoid |
Glucocorticoid |
Glucocorticoid prodrug |
| Common role |
Replacement and inflammatory therapy |
Physiologic replacement and inflammation |
Broad anti-inflammatory and immunosuppressive use |
| Relative clinical familiarity |
Lower than hydrocortisone and prednisone |
High |
High |
| Generic competition |
Extensive |
Extensive |
Extensive |
| Substitution risk |
High |
High |
High |
| Commercial differentiation |
Limited |
Some dosage-form differentiation |
Broad indication use |
| Patent barrier |
None of practical importance |
Mature generic market |
Mature generic market |
Hydrocortisone is the closest therapeutic comparator for adrenal replacement. Prednisone is a stronger competitor in inflammatory and immune-mediated indications. Dexamethasone and methylprednisolone compete in acute and specialty settings.
The choice among these products is often determined by pharmacokinetics, clinician preference, patient response, formulary rules, tablet availability, and conversion requirements rather than brand loyalty.
What formulations are protected by cortisone acetate patents?
No widely recognized active patent estate protects the standard immediate-release cortisone acetate tablet as a commercially differentiated platform. The conventional product has limited formulation complexity.
Possible technical barriers include:
- Control of tablet potency at low dose.
- Uniformity of content.
- Stability under moisture and heat.
- API particle-size control.
- Dissolution performance.
- Manufacturing scale-up and validation.
- Packaging that preserves stability.
These are execution barriers, not durable exclusivity barriers. A manufacturer with a reliable API source and validated tableting process can generally compete without licensing proprietary delivery technology.
No major commercial market has developed around long-acting, transdermal, injectable, or targeted cortisone acetate delivery systems. The absence of such products limits both patent density and premium pricing.
Are there Paragraph IV challenges involving cortisone acetate?
Paragraph IV litigation is unlikely to be commercially significant for standard cortisone acetate products because the core patents have expired and the product is already genericized. A current ANDA applicant would ordinarily not need to challenge a live molecule patent to enter the market.
A Paragraph IV certification could arise if an ANDA references a listed patent associated with a particular formulation, method of use, or approved product. Any such dispute would likely concern a narrow patent and would not restore broad market exclusivity for cortisone acetate.
Publicly material recent Paragraph IV litigation involving standard cortisone acetate is not a defining feature of the market. The more relevant legal risks are product-liability claims, manufacturing compliance, supply contracts, and regulatory enforcement.
What patent litigation and settlement agreements affect cortisone acetate?
There is no prominent current patent litigation or major generic settlement structure associated with the conventional cortisone acetate market. The product lacks the commercial revenue base that normally supports prolonged patent litigation or reverse-payment settlements.
Licensing activity is also limited. Companies may use:
- Contract manufacturing agreements.
- API supply agreements.
- Product-transfer agreements.
- Distribution arrangements.
- Portfolio acquisitions involving multiple generic products.
These transactions are usually not disclosed at the individual-product level. Cortisone acetate is more likely to be included in a portfolio transaction than licensed as a standalone strategic asset.
What is the FDA regulatory status of cortisone acetate?
FDA-approved cortisone acetate products are conventional prescription drugs. Current products generally rely on ANDAs demonstrating equivalence to an approved reference product.
Key regulatory risks include:
- Manufacturing-site inspections.
- API quality and supply continuity.
- Tablet potency and content uniformity.
- Dissolution and stability failures.
- Labeling compliance.
- Product discontinuation or temporary shortage.
- Changes in approved manufacturing sites.
FDA databases distinguish approved applications from products that are actively marketed. That distinction matters because a product can remain approved while having little or no commercial supply (FDA, 2024b).
What generic entry risks exist for cortisone acetate?
Generic entry risk is already fully realized. The relevant risk for incumbent suppliers is not new generic entry but additional supplier competition, price erosion, and loss of manufacturing scale.
The market has four principal commercial risks:
- A new low-cost supplier enters with adequate capacity.
- A current supplier exits because margins do not support compliance costs.
- An API or packaging disruption causes a temporary shortage.
- Hospitals and payers substitute another corticosteroid.
The most important countervailing risk is supply concentration. Mature generic products can have low prices that discourage multiple manufacturers from maintaining redundant capacity. A shortage can therefore occur even when the product has many theoretical approved suppliers.
How strong is the patent estate for cortisone acetate?
The patent estate is weak from an exclusivity perspective and largely irrelevant to investment value. Its strength can be summarized as follows:
| Patent metric |
Assessment |
| Composition-of-matter protection |
None remaining |
| Method-of-use protection |
No broad commercially controlling estate identified |
| Formulation protection |
Limited and unlikely to block ordinary tablets |
| Manufacturing protection |
Potentially narrow and design-aroundable |
| Orange Book leverage |
Low |
| Litigation leverage |
Low |
| Licensing leverage |
Low |
| Generic-entry barrier |
Minimal |
The product’s defensibility comes from operational execution, not intellectual property. A supplier with reliable quality, adequate inventory, and efficient distribution may outperform a larger patent holder because there is no meaningful patent holder controlling the market.
What is the financial trajectory for cortisone acetate?
The long-term financial trajectory is flat to declining in nominal terms, with intermittent price volatility caused by supply conditions. Volume is likely to remain stable in replacement therapy but does not have a strong growth catalyst.
Base-case trajectory
The base case is:
- Stable or modestly declining prescription volume.
- Continued generic price pressure.
- Low revenue per prescription.
- Limited promotional spending.
- Occasional supply-driven price increases.
- No material contribution from new indications.
- No likely premium for a conventional tablet formulation.
Upside scenario
An upside scenario could arise from:
- A shortage among competing suppliers.
- Acquisition of a low-cost approved product.
- Reliable supply to hospitals or government buyers.
- Expansion into underpenetrated international markets.
- Improved manufacturing economics.
- Portfolio bundling with other corticosteroids.
These factors could improve product-level margins but would not create a high-growth pharmaceutical franchise.
Downside scenario
The downside scenario includes:
- Supplier exit.
- API disruption.
- FDA warning letters or manufacturing remediation.
- Reimbursement compression.
- Increased substitution by hydrocortisone or prednisone.
- Product discontinuation caused by low margins.
For investors, cortisone acetate is unlikely to be a material standalone value driver unless it is part of a broader generic portfolio or benefits from a temporary supply shortage.
What geographic markets offer the greatest opportunity?
The United States provides a regulated, established market but has strong generic competition and limited pricing power. Europe and other developed markets also have mature corticosteroid supply and aggressive reimbursement controls.
Emerging markets may offer greater volume growth because of expanding diagnosis and access to essential medicines. Pricing remains constrained, and regulatory registration, local manufacturing rules, tender systems, and distribution infrastructure determine commercial viability.
Geographic opportunity is therefore operational rather than patent-driven. A company with local registration, government-tender capability, and dependable supply may generate more value than a company holding nominal formulation rights.
Key Takeaways
- Cortisone acetate is a mature generic corticosteroid with no meaningful original patent protection.
- The product has low revenue per prescription and no publicly disclosed standalone financial performance from major manufacturers.
- FDA market access is driven by ANDA approval, manufacturing compliance, and supply reliability.
- Orange Book and Paragraph IV issues are unlikely to create a broad barrier to generic entry.
- Hydrocortisone and prednisone are the main therapeutic substitutes.
- The main commercial opportunity is reliable low-cost supply, not innovation or patent exclusivity.
- Shortages can produce temporary pricing gains, but the long-term trajectory is generally flat to declining.
- Patent strength is weak; manufacturing and distribution execution determine competitive position.
- Biosimilar risk does not apply because cortisone acetate is a conventional small molecule.
- Licensing and litigation activity are unlikely to be material at the standalone product level.
FAQs About Cortisone Acetate Market Economics
Is cortisone acetate still commercially available?
Yes. Generic cortisone acetate tablets remain available in selected strengths, although active marketing and inventory can vary by manufacturer and market.
Can a company obtain new exclusivity for cortisone acetate?
A new product could potentially qualify for limited regulatory protection if it introduced a genuinely novel formulation or delivery system, but a conventional immediate-release tablet would not ordinarily create meaningful new exclusivity.
Is cortisone acetate more profitable than hydrocortisone?
Generally, no. Both are mature generic corticosteroids, but hydrocortisone has broader clinical use and more extensive dosage-form demand. Profitability depends more on supply position, manufacturing cost, and payer contracts than on the molecule itself.
Does cortisone acetate require a biosimilar application?
No. Biosimilar regulation applies to biological products. Cortisone acetate is a chemically synthesized small molecule and is generally approved through the ANDA framework when referencing an approved product.
Could cortisone acetate become a shortage-driven investment opportunity?
Potentially, but any opportunity would likely be temporary and dependent on verified supply disruption, available inventory, regulatory compliance, and the supplier’s ability to maintain production after competitors return.
References
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024c). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
-
U.S. Food and Drug Administration. (2024d). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
National Library of Medicine. (2024). DailyMed: Cortisone acetate labeling. https://dailymed.nlm.nih.gov/dailymed/
